These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1101256)

  • 1. The Paul H. Hoch Award lecture: Progress toward an understanding of the biological substrates of schizophrenia.
    Kety SS
    Proc Annu Meet Am Psychopathol Assoc; 1975; (63):15-26. PubMed ID: 1101256
    [No Abstract]   [Full Text] [Related]  

  • 2. The Paul H. Hoch Award Lecture: a followup study of the results of treatment of schizophrenia.
    May PR; Tuma AH
    Proc Annu Meet Am Psychopathol Assoc; 1976; (64):256-84. PubMed ID: 946683
    [No Abstract]   [Full Text] [Related]  

  • 3. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
    Kety SS
    Semin Psychiatry; 1972 Aug; 4(3):233-8. PubMed ID: 4155537
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biochemical approach to schizophrenia].
    Lipcsey A
    Orv Hetil; 1980 Nov; 121(47):2863-70. PubMed ID: 7219990
    [No Abstract]   [Full Text] [Related]  

  • 6. Central dopaminergic mechanisms in schizophrenia.
    Owen F; Crow TJ; Poulter M
    Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N-methyl-D-aspartate receptor and schizophrenia.
    Strous RD; Javitt DC
    Isr J Med Sci; 1996 May; 32(5):275-81. PubMed ID: 8641863
    [No Abstract]   [Full Text] [Related]  

  • 8. [Schizophrenia and cerebral amines].
    Véron JP; Kezirian S
    Presse Med (1893); 1971 Oct; 79(44):1973-4. PubMed ID: 5119550
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminergic abnormalities in postmortem schizophrenic brain.
    Mackay AV; Bird ED; Iversen LL; Spokes EG; Creese I; Snyder SH
    Adv Biochem Psychopharmacol; 1980; 24():325-33. PubMed ID: 7405668
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inadequacy of the monoamine oxidase system--the probable pathogenetic factor in schizophrenia (review)].
    Kolpakov VG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(8):1254-63. PubMed ID: 4278558
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic possibilities of cysteamine in the treatment of schizophrenia.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():53-5. PubMed ID: 6105799
    [No Abstract]   [Full Text] [Related]  

  • 13. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
    Jardemark K; Wadenberg ML; Grillner P; Svensson TH
    Curr Opin Investig Drugs; 2002 Jan; 3(1):101-5. PubMed ID: 12054059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.
    Riederer P; Lange KW; Kornhuber J; Danielczyk W
    Arzneimittelforschung; 1992 Feb; 42(2A):265-8. PubMed ID: 1350197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia.
    Morrison PD; Murray RM
    Curr Biol; 2005 Dec; 15(24):R980-4. PubMed ID: 16360673
    [No Abstract]   [Full Text] [Related]  

  • 18. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical aspects of schizophrenia.
    Lewis ME
    Essays Neurochem Neuropharmacol; 1980; 4():1-67. PubMed ID: 6104597
    [No Abstract]   [Full Text] [Related]  

  • 20. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
    Lideman RR; Zlobina GP; Mukhin AG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.